Daniel V Schidlow, M.D.  Journal of Cystic Fibrosis 

Slides:



Advertisements
Similar presentations
Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
Advertisements

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients  R. Cantón, N. Cobos,
Infections in Patients with Cystic Fibrosis
Is infection with hypermutable Pseudomonas aeruginosa clinically significant?  Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir 
Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients  Karen.
Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!  Clémence Martin, Cécile Hamard,
Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.
Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation 
Nadav Traeger, Qiuhu Shi, Allen J. Dozor  Journal of Cystic Fibrosis 
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M
Laura Viviani, Baroukh M. Assael, Eitan Kerem 
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study  Maret L. Maliniak, Arlene A.
Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
John Widger, Sarath Ranganathan, Philip J. Robinson 
Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection  Marita Gilljam, Henrik Scherstén, Martin Silverborn, Bodil.
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia  P.Ø. Jensen, C. Moser, A. Kharazmi,
A. Oliver, A. Mena  Clinical Microbiology and Infection 
Pulmonary exacerbations in CF patients with early lung disease
The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population  Brandie D. Wagner, Frank J. Accurso,
Controlled clinical trials in cystic fibrosis — are we doing better?
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
Claire Keating, Armeen D
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
Implementation of European standards of care for cystic fibrosis ��� Control and treatment of infection  J.S. Elborn, M. Hodson, C. Bertram  Journal of.
The Journal of Cystic Fibrosis: Sunny perspectives
A.H. Gifford  Journal of Cystic Fibrosis 
A specific database for providing local and national level of integration of clinical data in cystic fibrosis  T. Leal, G. Reychler, P. Mailleux, J. Gigi,
Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis  Elizabeth F. Shead, Charles S. Haworth,
Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden  Per Kristian Knudsen, Hanne.
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A
Meena Kalluri, MD, Janice Richman-Eisenstat, MD, FRCPC 
Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis  D.W. Reid, R. Latham, I.L.
Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi 
Marie-Angela Schnyder, Christian Benden, Christoph Schmid 
Calculation of the capnographic index based on expiratory molar mass–volume-curves — A suitable tool to screen for cystic fibrosis lung disease  Susanne.
Cytokine gene polymorphisms and severity of CF lung disease
Richard J Gralla, MD, Frank Griesinger, MD, PhD 
Nasal polyposis in lung transplant recipients with cystic fibrosis
Chee Y. Ooi, Peter R. Durie  Journal of Cystic Fibrosis 
Antine E. Stenbit, Wendy M. Bullington, Julie L. Heh, Patrick A. Flume 
Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis  K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic  Amanda L. Griffiths, Danielle F. Wurzel,
Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention  H. White, K. Pollard, C. Etherington, I. Clifton,
Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients  Valerie Waters, Eshetu G. Atenafu, Annie.
Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa  Karen O. McKay, Peter J. Cooper, Peter P. van.
Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale 
Ruth H. Keogh, Sanja Stanojevic  Journal of Cystic Fibrosis 
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation  Markus Hofer, Christoph Schmid, Christian Benden, Rudolf Speich,
H. White, A.M. Morton, S.P. Conway, D.G. Peckham 
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid 
D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher 
The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation  C. Etherington,
Beta-lactam allergy in adults with cystic fibrosis
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa  C.E. Wainwright, A.L. Quittner, D.E.
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P
Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005  Donald R. VanDevanter, Eric P. Elkin,
Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population  Elaine.
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience  C.R.
H. White, A.M. Morton, D.G. Peckham, S.P. Conway 
Chest imaging in cystic fibrosis studies: What counts, and can be counted?  Rhonda Szczesniak, Lidija Turkovic, Eleni-Rosalina Andrinopoulou, Harm A.W.M.
Presentation transcript:

“Maintaining the Horizontal Line”: early intervention and prevention of CF lung disease  Daniel V Schidlow, M.D.  Journal of Cystic Fibrosis  Volume 3, Issue 2, Pages 63-66 (June 2004) DOI: 10.1016/j.jcf.2004.05.044

Fig. 1 Diagrammatic representation of clinical course over time in Cystic Fibrosis. Meconium ileum is the earliest event. Affected individuals can be largely symptomatic or mildly symptomatic for variable periods of time (solid line) or start becoming increasingly symptomatic earlier in life (dotted line) and then suffer increasingly severe, frequent, and permanent signs and symptoms of pulmonary disease until death. Journal of Cystic Fibrosis 2004 3, 63-66DOI: (10.1016/j.jcf.2004.05.044)

Fig. 2 Diagrammatic representation of pulmonary function (PFT) over time. Exacerbations of lung disease result in drops in PFT, which are recoverable to “baseline” “The Horizontal” represents an ideal state of stability and normality. Clinical exacerbations and progression of lung disease lower the baseline progressively, until death or successful lung transplantation is achieved. Journal of Cystic Fibrosis 2004 3, 63-66DOI: (10.1016/j.jcf.2004.05.044)

Fig. 3 Survival by age against slope of decrease of flow rates. Steeper decreases result in decreased survival rate (adapted from Corey et al., J Pediatr 1997; 131:809–814, with permission). Journal of Cystic Fibrosis 2004 3, 63-66DOI: (10.1016/j.jcf.2004.05.044)

Fig. 4 Graphic representing the impact of Pseudomonas aeruginosa infection on survival of patients with CF (adapted from Henry, R.L. et al., Pediatr Pulmonol 1992;12:158–161; with permission from the publisher). Journal of Cystic Fibrosis 2004 3, 63-66DOI: (10.1016/j.jcf.2004.05.044)